< Arab Finance - News - Rameda reports 41.1% profit increase in H1
Count Down to relaunch

Rameda reports 41.1% profit increase in H1

Rameda reports 41.1% profit increase in H1

ArabFinance: Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) posted a consolidated net profit of EGP 61.47 million for the first half (H1) of 2021, up by 41.1% from EGP 43.47 million in H1 2020, according to the company’s financial statements filed to the Egyptian Exchange.

Meanwhile, Rameda reported a standalone net profit of EGP 81.26 million in the January-June period of 2021, compared to a net profit of EGP 44.05 million in H1 2020.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

#Related keywords

Recommended Stocks

13 Jun 2022
Delta Sugar SUGR

All rights reserved to Arab Finance 2020 ©

Back to top